MA, United States
MA, United States

Time filter

Source Type

News Article | May 22, 2017
Site: www.prnewswire.com

"This study provides the most robust view available on the prevalence of CSA in patients on PAP therapy," said Dr. Carlos Nunez, ResMed's chief medical officer. "The findings in this new research, combined with the research presented in April 2017, underscore the importance of keeping patients on therapy through regular monitoring, and rethinking the conventional wisdom on therapeutic options based on each patient's disease severity." The new analysis defined three groups among patients with CSA – emergent, persistent and transient – based on whether the condition was present at the start of therapy or emerged during the first 12 weeks. All three groups showed a significantly higher risk of terminating their therapy than those without CSA. The risk was highest among the emergent group, whose CSA only became apparent during treatment, and were 1.7 times more likely to terminate their therapy than those without the condition. About the Study The study authors included: Atul Malhotra, University of California San Diego, United States; Peter Cistulli, University of Sydney, Australia; and Jean-Louis Pépin, Grenoble Alpes University, France. A retrospective analysis used anonymous, aggregated telemonitoring data from a U.S. positive airway pressure therapy database, (ResMed AirView™) and analyzed it for the presence or absence of CSA during CPAP therapy at baseline (week 1) and after 12 weeks. Session data included weekly values by averaging within each week for each patient. Defined patient groups were: OSA, emergent CSA, persistent CSA and transient CSA. Groups were compared to identify risk factors for different forms of CSA, and adherence and therapy termination rates were determined. Patients with any form of CSA during CPAP were at higher risk of terminating therapy in the first 90 days versus those who did not develop CSA (hazard ratio 1.7 for emergent CSA, 1.4 for persistent CSA and 1.3 for transient CSA; all p<0.001). About Central Sleep Apnea Obstructive sleep apnea (OSA) and central sleep apnea (CSA) are the two most common types of sleep apnea, a condition that results in repetitive pauses in breathing during sleep. OSA is a sleep disorder in which the throat muscles relax, block the airways and stop the flow of breath during sleep. CSA is a sleep disorder in which the brain does not transmit the "breathe" signal to the muscles that control breathing during sleep. In either situation, the lack of oxygen causes the person to wake up to catch their breath and start breathing again, interrupting continuous sleep. This may occur multiple times in an hour. In some patients with OSA, CSA may emerge and only become apparent during CPAP therapy. This was recognized in the third edition of the International Classification of Sleep Disorders and called "treatment-emergent CSA". About ResMed ResMed (NYSE: RMD) changes lives with award-winning medical devices and cloud-based software applications that diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is the global leader in connected care, with more than 3 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.­­ ResMed.com | Facebook | Twitter | LinkedIn 1 References:  Gami AS et al. Circulation 2004,  O'Keefe and Patterson, Obes Surgery 2004, Logan et al. J. Hypertension 2001, O'Keeffe T and Patterson EJ. Obes Surg 2004, Einhorn D et al. Endocr Pract 2007, Bassetti C and Aldrich M. Sleep 1999 2 ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnea. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/big-data-yields-big-insights-for-treatment-of-central-sleep-apnea-300461209.html


"ResMed filed a motion to dismiss the current International Trade Commission (ITC) complaint so that we can refile and incorporate additional evidence generated since the original complaint was filed. We believe this will make our strong case even stronger, and we remain confident in our position in the ITC. ResMed's innovations have transformed the treatment of sleep-disordered breathing. We're committed to protecting our innovation, which is why we've engaged in global legal proceedings with Fisher & Paykel." About ResMed ResMed (NYSE: RMD) changes lives with award-winning medical devices and cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.­­ ResMed.com | Facebook | Twitter | LinkedIn


SAN DIEGO, May 17, 2017 /PRNewswire/ -- ResMed today issued the following statement from David Pendarvis, the company's global general counsel and chief administrative officer: "ResMed filed a motion to dismiss the current International Trade Commission (ITC) complaint so that we can refile and incorporate additional evidence generated since the original complaint was filed. We believe this will make our strong case even stronger, and we remain confident in our position in the ITC. ResMed's innovations have transformed the treatment of sleep-disordered breathing. We're committed to protecting our innovation, which is why we've engaged in global legal proceedings with Fisher & Paykel." About ResMed ResMed (NYSE: RMD) changes lives with award-winning medical devices and cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company - improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.­­ ResMed.com | Facebook | Twitter | LinkedIn


News Article | May 21, 2017
Site: www.prnewswire.com

Patients in the study who received NIV at home in addition to oxygen therapy had a 51 percent decreased risk of re-hospitalization or death, and stayed out of the hospital more than three times longer, compared to those who received oxygen alone. "This trial adds decisively to the growing body of evidence supporting the broader use of non-invasive ventilation for patients with COPD," said ResMed chief medical officer Carlos Nunez, M.D. "Just knowing NIV can help cut re-hospitalization or death risk in half is a game changer." The Global Initiative for Obstructive Lung Disease, an international collaboration of experts on COPD, recently updated their guidelines to include a level B recommendation for home NIV for hypercapnic COPD patients after an exacerbation. The number of people with COPD globally is estimated to be 384 million1. In 2014, the Centers for Disease Control and Prevention (CDC) estimated COPD cost the United States $36 billion annually in medical costs and absenteeism, and projected medical costs alone related to COPD could rise to $49 billion by 2020. One reason is that nearly one in four COPD patients in the U.S. who leave the hospital after an acute exacerbation will be re-hospitalized within 30 days, driving increased costs to the healthcare system and significantly impacting the patients' quality of life. To curb the financial impact of this re-hospitalization, the U.S. Centers for Medicare and Medicaid Services now penalizes hospitals with high readmission rates after an acute exacerbation of COPD. More details on the study can be found on the JAMA website: http://jamanetwork.com/journals/jama/fullarticle/2627985. COPD is a collection of lung diseases including chronic bronchitis and emphysema. It is a progressive, fatal condition that causes irreversible damage to the lungs and airways. It can have a major impact on an individual's quality of life. It is the third leading cause of death in the U.S. and is the only major disease that is increasing in prevalence globally, across all continents. During the course of their disease, COPD patients can experience acute exacerbations, which manifest themselves as a sudden worsening of symptoms and can lead to respiratory failure, hospitalization and death. Although the damage caused by COPD cannot be reversed, it is possible to slow the progression of the disease through treatment and lifestyle changes. ResMed (NYSE: RMD) changes lives with award-winning medical devices and cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.­­ ResMed.com | Facebook | Twitter | LinkedIn 1 Global and regional estimates of COPD prevalence: Systematic review and meta–analysis, Journal of Global Heath, 2015 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/clinical-trial-published-in-jama-offers-new-hope-for-copd-patients-300461130.html


The Solidification Using a Baffle in Sealed Ampoules (SUBSA) hardware being installed by NASA astronaut Peggy Whitson during Expedition 5. The SUBSA Furnace and Inserts investigation includes modernized data acquisition, high definition video and communication interfaces. Credit: NASA Research into crystal growth in microgravity was one of the earliest investigations conducted aboard the International Space Station and is continued to this day. The unique microgravity environment of space provides an ideal setting for producing crystals that are more perfect than their terrestrial-grown counterparts. The Crystal Growth of Cs2LiYCl6:Ce Scintillators in Microgravity (CLYC-Crystal Growth), a Center for the Advancement of Science in Space (CASIS)-sponsored investigation, will study the potential benefits of growing the CYLC crystal in microgravity. The CLYC crystal is a special kind of multicomponent crystal system used to make scintillator radiation detectors, a device that is sensitive to both gamma rays and neutrons. "It's a spectroscopic crystal, which means, using this crystal, we can detect the presence and intensity of radiation, as well as identify which isotopes emit radiation by measuring the energy," said Dr. Alexei Churilov, primary investigator and senior scientist at Radiation Monitoring Devices Inc. (RMD). The CLYC crystal is produced as a commercial product by RMD and is largely used to detect and differentiate both harmful and harmless levels of radiation. The crystal's main application is homeland security as a method of detected smuggled nuclear materials, but may also be used for oil and gas exploration, medical imaging, particle and space physics and scientific instruments. However, the Earth-grown crystals have shown defects such as cracks, grain boundaries and inclusions, incidents which scientists like Churilov hope to eliminate by using the space station's microgravity environment as a growth habitat. Research has shown that many, though not all, crystals benefit from growth in microgravity. Although the reasoning behind this phenomena is still being investigated, research points to the lack of buoyancy-induced convection, which affects transport of molecules in the crystal. "Our ultimate goal is to study the growth of CLYC in microgravity without the interference of convection and to improve the production of the crystal on Earth," said Churilov. The research for the CLYC Crystal Growth investigation will be conducted within the Solidification Using a Baffle in Sealed Ampoules Furnaces and Inserts (SUBSA Furnaces and Inserts). SUBSA helps researchers advance the understanding of processes involved in semiconductor crystal growth. It offers a gradient freeze furnace for materials science investigations. SUBSA was originally operated aboard the space station in 2002, the SUBSA hardware has been modernized and updated with data acquisition, high resolution video and communication interfaces. During the investigation, four crystal growth runs will be conducted aboard the space station and then in the ground-based SUBSA furnaces, giving researchers a view into the gravitational effect on their growth. Once the investigation is complete, the space-grown crystals will be compared against their counterparts on Earth and tested for imperfections and effectiveness as radiation detectors. Although microgravity can't be mimicked or reproduced on the ground, results from the investigation will provide information about which crystal methods to use on Earth, how to improve ampoule and furnace design and which crystal growth parameters to change in pursuit of a more perfect crystallization process. Though the total weight of the CLYC Crystal Growth investigation is small, only a few kilograms together with packaging, the benefits can be immense as the data gathered during the investigation will be put to immediate use in the production of CLYC crystals.


Trojan-Piegza J.,Boston University | Trojan-Piegza J.,Wrocław University | Glodo J.,RMD Inc. | Sarin V.K.,Boston University
Radiation Measurements | Year: 2010

A series of composites of CaF2(Eu2+) and LiF with different Ca/Li ratios were fabricated via liquid phase consolidation. Luminescent properties of these samples were investigated. Radioluminescence shows the typical Eu2+ blue emission in all the compositions. The energy spectra measured under γ and neutron irradiation indicates that the most promising composition for neutron detection is the eutectic. © 2010 Elsevier Ltd. All rights reserved.


Sengupta D.,Stanford University | Miller S.,RMD Inc. | Marton Z.,RMD Inc. | Chin F.,Stanford University | And 2 more authors.
Advanced Healthcare Materials | Year: 2015

The performance of a new thin-film Lu2O3:Eu scintillator for single-cell radionuclide imaging is investigated. Imaging the metabolic properties of heterogeneous cell populations in real time is an important challenge with clinical implications. An innovative technique called radioluminescence microscopy has been developed to quantitatively and sensitively measure radionuclide uptake in single cells. The most important component of this technique is the scintillator, which converts the energy released during radioactive decay into luminescent signals. The sensitivity and spatial resolution of the imaging system depend critically on the characteristics of the scintillator, that is, the material used and its geometrical configuration. Scintillators fabricated using conventional methods are relatively thick and therefore do not provide optimal spatial resolution. A thin-film Lu2O3:Eu scintillator is compared to a conventional 500 μm thick CdWO4 scintillator for radioluminescence imaging. Despite its thinness, the unique scintillation properties of the Lu2O3:Eu scintillator allow us to capture single-positron decays with fourfold higher sensitivity, which is a significant achievement. The thin-film Lu2O3:Eu scintillators also yield radioluminescence images where individual cells appear smaller and better resolved on average than with the CdWO4 scintillators. Coupled with the thin-film scintillator technology, radioluminescence microscopy can yield valuable and clinically relevant data on the metabolism of single cells. © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.


Tian L.,Massachusetts Institute of Technology | Tian L.,University of California at Berkeley | Petruccelli J.C.,Massachusetts Institute of Technology | Miao Q.,Massachusetts Institute of Technology | And 4 more authors.
Optics Letters | Year: 2013

We develop and implement a compressive reconstruction method for tomographic recovery of refractive index distribution for weakly attenuating objects in a microfocus x-ray system. This is achieved through the development of a discretized operator modeling both the transport of intensity equation and the x-ray transform that is suitable for iterative reconstruction techniques. © 2013 Optical Society of America.


Trademark
Rmd Llc | Date: 2012-07-24

heat and acoustical composite insulating shield for automobiles, trucks, boats, watercraft, HVAC, appliances and machinery; insulating tapes; adhesive sealant and caulking compound.


WATERTOWN, Mass., Nov. 2, 2016 /PRNewswire/ -- Dynasil Corporation of America (NASDAQ: DYSL) today announced that its subsidiary, RMD Inc., will be supplying Thermo Fisher Scientific with packaged solid state detectors based on RMD's Cs2LiYCl6:Ce (CLYC) scintillation crystals for use in...

Loading RMD Inc collaborators
Loading RMD Inc collaborators